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Abstract
Background: The human genome displays extensive copy-number variation (CNV). Recent discoveries have shown 
that large segments of DNA, ranging in size from hundreds to thousands of nucleotides, are either deleted or 
duplicated. This CNV may encompass genes, leading to a change in phenotype, including drug response phenotypes. 
Gemcitabine and 1-β-D-arabinofuranosylcytosine (AraC) are cytidine analogues used to treat a variety of cancers. 
Previous studies have shown that genetic variation may influence response to these drugs. In the present study, we set 
out to test the hypothesis that variation in copy number might contribute to variation in cytidine analogue response 
phenotypes.
Results: We used a cell-based model system consisting of 197 ethnically-defined lymphoblastoid cell lines for which 
genome-wide SNP data were obtained using Illumina 550 and 650 K SNP arrays to study cytidine analogue cytotoxicity. 
775 CNVs with allele frequencies > 1% were identified in 102 regions across the genome. 87/102 of these loci 
overlapped with previously identified regions of CNV. Association of CNVs with gemcitabine and AraC IC50 values 
identified 11 regions with permutation p-values < 0.05. Multiplex ligation-dependent probe amplification assays were 
performed to verify the 11 CNV regions that were associated with this phenotype; with false positive and false negative 
rates for the in-silico findings of 1.3% and 0.04%, respectively. We also had basal mRNA expression array data for these 
same 197 cell lines, which allowed us to quantify mRNA expression for 41 probesets in or near the CNV regions 
identified. We found that 7 of those 41 genes were highly expressed in our lymphoblastoid cell lines, and one of the 
seven genes (SMYD3) that was significant in the CNV association study was selected for further functional experiments. 
Those studies showed that knockdown of SMYD3, in pancreatic cancer cell lines increased gemcitabine and AraC 
resistance during cytotoxicity assay, consistent with the results of the association analysis.
Conclusions: These results suggest that CNVs may play a role in variation in cytidine analogue effect. Therefore, 
association studies of CNVs with drug response phenotypes in cell-based model systems, when paired with functional 
characterization, might help to identify CNV that contributes to variation in drug response.
Background
It is known that inherited genomic CNV is linked to risk
for human disease and response to treatment. It has also
been established for decades that genomic variation,
including CNV in germline DNA, can help predict varia-
tion in efficacy and/or adverse responses to therapeutic
drugs [1-5]. For example, individuals with multiple copies
of the gene encoding the drug metabolizing enzyme
CYP2D6 are "ultrarapid" metabolizers as compared to
those with CYP2D6 deletions ("poor" metabolizers), and
these genotypes are associated with variation in response
to a large number of drugs [4,6]. CNVs within the human
genome are not rare events. Redon et. al. [7] identified
nearly 1,500 CNV regions scattered throughout the
genome in 270 HapMap samples. Those regions com-
prised approximately 10% of the human genome, encom-
passing coding and non-coding regions, as compared to
the < 1% of the genome that is occupied by SNP s [8].
CNVs appear to be present at lower frequencies than
SNPs [9], but this may be due in part to the techniques
utilized to identify them. Thus, the prevalence and bio-
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logical significance of CNVs may be underestimated. As
of early 2009, nearly 6,225 CNV loci had been cataloged
by the Database of Genomic Variants http://proj-
ects.tcag.ca/variation/. In addition, nearly 18% of mRNA
species that are genetically regulated through cis effects
c o u l d  b e  e x p l a i n e d  b y  C N V s  [ 1 0 ] .  T o g e t h e r  w i t h  S N P
genotypes, CNV data can be generated with SNP arrays
[7,9,11-13]. Although these methodologies have limita-
tions [14], CNVs, depending on their size and location,
may be just as important for variation in function as are
SNPs.
The cytidine analogues, gemcitabine and AraC, show
significant therapeutic effect in several types of cancer.
Gemcitabine is mainly used to treat solid tumors [15,16]
while AraC is used to treat acute myelogenous leukemia
[17]. Clinical response to these two drugs varies widely,
and previous studies showed that inheritance can con-
tribute to the variation in response of these two drugs
[18]. In this study, we set out to test the hypothesis that
CNV might contribute to variation in gemcitabine and
AraC response in 197 EBV transformed lymphoblastoid
cell lines using SNP data obtained with Illumina 550 and
650 K SNP arrays.
Methods
Genotyping and populations
A subset of the "Human Variation Panel" lymphoblastoid
cell lines consisting of 60 Caucasian-American (CA), 54
African-American (AA), and 60 Han Chinese-American
(HCA), as well as 23 CEPH Caucasian HapMap EBV
transformed cell lines was obtained from the Coriell Cell
Repository (Camden, NJ). These cell lines had been
obtained from healthy individuals and were anonymized
by the National Institute of General Medical Sciences
prior to deposit. All of these individuals had provided
written consent for the use of their cells and DNA from
those cells to be used for experimental purposes. We gen-
otyped the AA DNA from these cell lines using the Illu-
mina Human Hap 650 beadchip (Human660W-Quad v1),
and the Illumina Human Hap 550 beadchips were used to
genotype the remainder of the samples. All samples were
genotyped in the Mayo Clinic Genotyping Core Facility.
All but two samples had a call rate greater than 98%, and
those two samples, even after repetition, had call rates
between 95 and 98%. We assessed LRR standard devia-
tion (SD) for our samples and found that none of the sam-
ples had a SD less than 0.21. Quality control (QC)
recommendations for the PennCNV or QuantiSNP algo-
rithms suggest using a SD < 0.3 [19]. Since, our LRR stan-
dard deviation did not exceed this QC threshold; we also
used those two samples in the analysis. For consistency,
we did not include the additional 100 K SNPs genotyped
for the AA samples in the CNV analysis.
Copy number identification
Bead Studio version 3.1 was used to obtain log R ratios
and B allele frequencies for 550,000 SNPs in the 197 sam-
ples studied. LogR ratios were generated by comparing
our experimental LogR values to Bead Studio's built in
multi-ethnic HapMap population. CNV genotyping was
performed using an Objective Bayes Hidden-Markov
model (QuantiSNP) [20] plug-in within Illumina's Bead
Studio interface. QuantiSNP is a statistical algorithm that
utilizes joint information with regard to log R ratios and B
allele frequencies for quantitative SNP array data analysis
that allows for precise discovery and mapping of copy
number changes. We used the QuantiSNP parameters
recommended by Illumina: expectation maximization =
10, CNV length = 10,000, maximum copy number
returned = 4, no GC content normalization, and score
threshold = 50. After applying the QuantiSNP algorithm,
we exported the CNV values and confidence values for
each SNP out of the Bead Studio software. Using our own
in-house programs written in R and Perl, we then sepa-
rated all SNPs associated with CNVs that were observed
in two or more samples (frequency > 1%). These thresh-
olds and parameters were set conservatively to accurately
identify CNVs under these conditions. This approach
should reduce the false positive rate, but at the risk of
increasing the false negative rate and missing more com-
mon, yet smaller CNVs that are inherently more difficult
to detect. After transforming CNV values for each SNP
into deletion (CNV value < 2), normal (CNV value = 2) or
amplification (CNV value > 2), distinct copy number
regions were obtained by merging neighboring SNPs with
identical CNVs across samples. A detailed description of
the methods used is available in the Additional file 1
Methods Section.
Copy number validation
Eleven copy number regions found to be associated with
gemcitabine and AraC IC50 values (p < 0.05) were selected
for validation using multiplex ligation-dependent probe
amplification (MLPA). Oligonucleotides were preferen-
tially designed based on a successful assay, followed by
selection for coding sequences and underlying p-values.
M13 sequence was attached to each probe together with a
complementary FlexMap100 sequence (Luminex, Aus-
tin, TX). Specifically, 80 ng of DNA was denatured at
98°C for 5 minutes, followed by 25°C for 1 minute. In an 8
μL reaction, 80 ng of DNA and 0.3 femtomole/μL of each
probe were mixed with 1.5 μL of MLPA buffer (MRC-
Holland, Amsterdam, Netherlands). Probes were allowed
to hybridize at 60°C for 16-24 hours. Probes were ligated
in a reaction containing 25 μl H2O, 3 μL Ligase-65 Buffer
A and B (MRC-Holland), and 1 μL Ligase-65 (MRC-Hol-
land) at 54°C for 15 minutes, followed by 98°C for 5 min-
u t e s .  E a c h  5 0  μ L  P C R  r e a c t i o n  c o n s i s t e d  o f  1 0  μ L  o fKalari et al. BMC Genomics 2010, 11:357
http://www.biomedcentral.com/1471-2164/11/357
Page 3 of 14
ligated product mixed with 27.5 μL H2O, 5 μL 10 × buffer
(Invitrogen, Carlsbad, CA), 1.5 μL 50 mM MgCl2 (Invitro-
gen), 4 μL 10 mM dNTPs (Applied Biosystems, Foster
City, CA), 0.5 μL 10 μM M13 primers, and 1 μL Platinum
Taq (Invitrogen). 10 μL of PCR product was then added
to 40 μL of bead mix containing 2,000 beads for each
FlexMap Microsphere (Luminex) suspended in 1 ×
TMAC, and the mixture was incubated at 96°C for 2 min-
utes, followed by 37°C for 60 minutes. Following incuba-
tion, 0.2 μL of Streptavidin R-Phycoerythrin Conjugate
(Invitrogen) plus 25 μL of 1 × TMAC was added and
incubated at room temperature for 30 minutes. Samples
were assayed on a LiquiChip 100IS System (Qiagen,
Valencia, CA) and results were analyzed with Gene-
Marker 1.6 software. Of the 11 CNV assayed, one
(chr14CNV87:106047919-106066496), did not provide
adequate signal intensity for analysis.
MTS assay
AraC was purchased from Sigma-Aldrich (St. Louis, MO)
and gemcitabine was provided by Eli Lilly (Indianapolis,
IN). Cytotoxicity assays were performed with the CellTi-
ter 96® Aqueous Non-Radioactive Cell Proliferation Assay
(Promega Corporation, Madison, WI). The drug concen-
trations used to perform these experiments were
described in detail previously by Li et al., 2008 [18].
Statistical analysis
The cytotoxicity phenotype (IC50) was determined on the
basis of the best fitting curve, either 4 parameter logistic,
4 parameter logistic with top = 100%, or 4 parameter
logistic with bottom = 0%. The curves were constructed
using the dose response curves package in R. The logistic
model with the lowest mean square error was used to
determine IC50  values for gemcitabine and AraC as
described in Li et al. [18]. Drug response phenotypes
(IC50 values) for both drugs were adjusted for ethnicity,
gender and storage time of the 197 samples using linear
regression (natural log transformation applied to IC50 val-
ues). In addition, CNV values were adjusted for ethnicity
and gender. Linear regression was then used to perform
association with adjusted CNV values (residuals from
regressing CNV against ethnicity and gender) with
adjusted IC50 phenotypes (residuals from regressing log
IC50 against ethnicity, gender and storage time). P-values
for association were obtained after performing 1000 per-
mutations for both gemcitabine and AraC IC50 values.
Transient transfection and RNA interference
Human MiaPaca-2 pancreatic cancer cells were trans-
fected with siRNA using Lipofectamine RNAMAX
(Invitrogen). Specifically, cells were seeded into 96-well
plates and were mixed with siRNA-complex containing
50 nM specific or negative control siRNA (Qiagen) and
transfection reagent (Invitrogen) in Opti-MEM®  I
Reduced Serum Media (Invitrogen). Forty eight hours
post-transfection, cells were harvested for cell-based
assays. SMYD3 siRNA and negative control siRNA were
purchased from Qiagen and were used as suggested by
the manufacturer.
Sequences for siRNA against SMYD3 were: Sense
strand: GGC GAU CAU AAG CAG CAA UdTdT CGA
UUA UAA UAA AUU CAA CdTdT
Antisense strand: AUU GCU GCU UAU GAU CGC
CdTdT UUU GAA UUU AUU AUA AUC GdTdG
Sequences for negative control siRNA were:
Sense strand: UUC UCC GAA CGU GUC ACG UdTdT
Antisense strand: ACG UGA CAC GUU CGG AGA
AdTdT
Real-time quantitative reverse transcription-PCR
Total RNA was isolated from cultured cells with the Qia-
gen RNeasy kit (Qiagen), followed by QRT-PCR per-
formed wit h t he 1-step, Brillian t II SYBR Green QR T -
PCR master mix kit (Stratagene, La Jolla, CA). Specifi-
cally, primers purchased from Qiagen were used to per-
form QRT-PCR using the Stratagene Mx3005P™ Real-
Time PCR detection system (Stratagene). All experiments
were performed in triplicate with β-actin as an internal
control. Control reactions lacked RNA template.
Results
CNV identification
We used the QuantiSNP parameters recommended by
Illumina for copy number identification. The QuantiSNP
algorithm in Illumina provided CNV values and confi-
dence values for each SNP and sample. After pre-process-
ing the data, we had 73,738 SNPs with CNV values other
than "normal" (CNV value = 2). 1,674 SNPs were retained
in the analysis after excluding SNPs that did not display
variation in at least two samples (minor allele frequency >
1%). We then applied a simple segregation algorithm as
described in Additional file 1 Methods and identified 775
CNVs at 102 loci using the 197 DNA samples obtained
from 3 ethnic groups. Figure 1 shows the CNV call results
using CNV region display in Bead Studio Software for 15
samples selected randomly from among the 197 samples
assayed. From the randomly selected data displayed in
Figure 1, it is clear that specific CNV regions could be
associated with multiple DNA samples. Copy number
loci or regions can also have multiple forms of variation,
probably as a result of different breakpoints. The mean
and median CNV frequencies per sample were 3.9 and
4.0, respectively, with a maximum value of 10. The 102
CNV loci identified represented 7.8 Mb of sequence, with
an average length of 77 kb and a median of 20 kb (90 bp to
1.7 Mb) (T able 1). T wenty five CNV s identified in thisKalari et al. BMC Genomics 2010, 11:357
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Table 1: CNV regions identified in 197 DNA samples.
CNV_ID Start Stop Size AA CA HCA Combined CNV Frequency
chr1CNV1 12789177 12834675 45498 0.036 0.024 0.050 0.035
chr1CNV2 94906770 94925850 19080 0.091 0.000 0.000 0.025
chr1CNV3 105966892 106000090 33198 0.055 0.000 0.017 0.020
chr1CNV4 147306690 147414362 107672 0.036 0.012 0.000 0.015
chr1CNV5 187665261 187809352 144091 0.000 0.000 0.083 0.025
chr1CNV6 195092486 195160949 68463 0.073 0.000 0.083 0.045
chr1CNV7 243707190 243713984 6794 0.000 0.036 0.000 0.015
chr2CNV8 41092376 41099005 6629 0.273 0.024 0.017 0.091
chr2CNV9 57281457 57295357 13900 0.000 0.036 0.000 0.015
chr2CNV10 89397452 89877778 480326 0.036 0.060 0.017 0.040
chr2CNV11 110228954 110315618 86664 0.036 0.012 0.050 0.030
chr2CNV12 184808081 184866619 58538 0.127 0.012 0.000 0.040
chr2CNV13 242566407 242653950 87543 0.000 0.084 0.000 0.035
chr3CNV14 6194326 6211038 16712 0.073 0.000 0.000 0.020
chr3CNV15 53003415 53010084 6669 0.000 0.048 0.017 0.025
chr3CNV16 65168286 65187636 19350 0.018 0.120 0.117 0.091
chr3CNV17 75535790 75610832 75042 0.000 0.036 0.000 0.015
chr3CNV18 101837214 101854561 17347 0.000 0.036 0.000 0.015
chr3CNV19 152997395 153028291 30896 0.000 0.036 0.000 0.015
chr3CNV20 163614102 163617940 3838 0.018 0.060 0.000 0.030
chr3CNV21 163701543 163710564 9021 0.000 0.012 0.283 0.091
chr3CNV22 166750382 166766442 16060 0.036 0.012 0.000 0.015
chr3CNV23 177371924 177397828 25904 0.000 0.072 0.000 0.030Kalari et al. BMC Genomics 2010, 11:357
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chr3CNV24 189070613 189088009 17396 0.000 0.012 0.033 0.015
chr3CNV25 192548615 192550982 2367 0.000 0.120 0.000 0.051
chr4CNV26 64386888 64391664 4776 0.000 0.024 0.033 0.020
chr4CNV27 64780488 64795145 14657 0.000 0.000 0.050 0.015
chr4CNV28 88405746 88445557 39811 0.055 0.000 0.000 0.015
chr4CNV29 104433739 104454829 21090 0.091 0.000 0.000 0.025
chr4CNV30 161277505 161290832 13327 0.000 0.060 0.000 0.025
chr4CNV31 162083578 162175279 91701 0.000 0.012 0.083 0.030
chr5CNV32 9955403 9976731 21328 0.036 0.036 0.000 0.025
chr5CNV33 97075236 97107276 32040 0.036 0.036 0.000 0.025
chr5CNV34 117418457 117420311 1854 0.109 0.060 0.000 0.056
chr5CNV35 120337992 120440119 102127 0.055 0.000 0.000 0.015
chr5CNV36 160474752 160479606 4854 0.000 0.000 0.050 0.015
chr2CNV37 67076651 67104015 27364 0.018 0.181 0.000 0.081
chr6CNV38 79031111 79086086 54975 0.255 0.410 0.083 0.268
chr6CNV39 93632051 93634213 2162 0.073 0.000 0.017 0.025
chr6CNV40 167619368 167688151 68783 0.055 0.000 0.000 0.015
chr7CNV41 64334979 64553672 218693 0.000 0.024 0.033 0.020
chr7CNV42 76038186 76394983 356797 0.073 0.036 0.033 0.045
chr7CNV43 81761377 81761849 472 0.000 0.000 0.050 0.015
chr7CNV44 89187436 89247424 59988 0.036 0.012 0.000 0.015
chr7CNV45 141420759 141433796 13037 0.036 0.060 0.067 0.056
chr8CNV46 3775146 3776955 1809 0.055 0.036 0.050 0.045
chr8CNV47 3987675 3990899 3224 0.073 0.000 0.000 0.020
chr8CNV48 5583294 5591685 8391 0.018 0.036 0.000 0.020
Table 1: CNV regions identified in 197 DNA samples. (Continued)Kalari et al. BMC Genomics 2010, 11:357
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chr8CNV49 13643904 13652680 8776 0.036 0.012 0.000 0.015
chr8CNV50 13657871 13680110 22239 0.182 0.012 0.000 0.056
chr8CNV51 16307052 16309085 2033 0.018 0.048 0.000 0.025
chr8CNV52 72378670 72378984 314 0.000 0.036 0.000 0.015
chr8CNV53 137757412 137919630 162218 0.018 0.036 0.000 0.020
chr9CNV54 507715 513495 5780 0.055 0.000 0.000 0.015
chr9CNV55 581094 597738 16644 0.073 0.000 0.000 0.020
chr9CNV56 5376384 5382199 5815 0.109 0.000 0.000 0.030
chr9CNV57 9782326 9786116 3790 0.000 0.000 0.050 0.015
chr9CNV58 11941204 12175185 233981 0.018 0.000 0.067 0.025
chr10CNV59 20891019 20894574 3555 0.000 0.036 0.033 0.025
chr10CNV60 45489854 47173619 1683765 0.200 0.157 0.050 0.136
chr10CNV61 58186118 58188682 2564 0.036 0.024 0.000 0.020
chr10CNV62 58583657 58603555 19898 0.000 0.000 0.067 0.020
chr10CNV63 122759910 122774261 14351 0.127 0.000 0.000 0.035
chr10CNV64 135116379 135219995 103616 0.073 0.060 0.017 0.051
chr11CNV65 5858528 5889688 31160 0.000 0.000 0.050 0.015
chr11CNV66 21145662 21170916 25254 0.109 0.012 0.000 0.035
chr11CNV67 25574425 25580720 6295 0.036 0.012 0.000 0.015
chr11CNV68 25662734 25676867 14133 0.127 0.012 0.000 0.040
chr11CNV69 55139733 55201444 61711 0.036 0.120 0.267 0.141
chr11CNV70 55217364 55346872 129508 0.036 0.000 0.000 0.010
chr11CNV71 81182373 81192815 10442 0.018 0.120 0.117 0.091
chr11CNV72 99154024 99156143 2119 0.000 0.012 0.050 0.020
Table 1: CNV regions identified in 197 DNA samples. (Continued)Kalari et al. BMC Genomics 2010, 11:357
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chr11CNV73 132499814 132509446 9632 0.000 0.036 0.000 0.015
chr11CNV74 134154053 134211153 57100 0.018 0.036 0.000 0.020
chr12CNV75 7888157 7982106 93949 0.018 0.000 0.050 0.020
chr12CNV76 19364102 19442103 78001 0.000 0.024 0.017 0.015
chr12CNV77 31180151 31298076 117925 0.036 0.060 0.017 0.040
chr12CNV78 62269256 62415375 146119 0.036 0.012 0.033 0.025
chr12CNV79 69162075 69162165 90 0.018 0.024 0.033 0.025
chr12CNV80 126056007 126056525 518 0.055 0.000 0.017 0.020
chr12CNV81 127794683 127830402 35719 0.000 0.012 0.017 0.010
chr12CNV82 130297674 130314013 16339 0.000 0.024 0.017 0.015
chr12CNV83 130368913 130378451 9538 0.036 0.024 0.033 0.030
chr14CNV84 43576901 43584372 7471 0.000 0.000 0.133 0.040
chr14CNV85 85358666 85376726 18060 0.018 0.024 0.000 0.015
chr14CNV86 85540054 85557089 17035 0.000 0.036 0.000 0.015
chr14CNV87 105997070 106237639 240569 0.073 0.157 0.067 0.106
chr15CNV88 30298847 30301633 2786 0.073 0.012 0.033 0.035
chr15CNV89 32530025 32587887 57862 0.127 0.072 0.067 0.086
chr15CNV90 32724681 32757729 33048 0.000 0.036 0.000 0.015
chr17CNV91 6047837 6061766 13929 0.036 0.012 0.000 0.015
chr17CNV92 14988424 14998870 10446 0.000 0.000 0.117 0.035
chr18CNV93 1915033 1964966 49933 0.018 0.036 0.000 0.020
chr18CNV94 64898548 64905367 6819 0.018 0.036 0.333 0.121
chr18CNV95 65360121 65362926 2805 0.000 0.036 0.017 0.020
chr19CNV96 15641747 15690364 48617 0.091 0.000 0.000 0.025
Table 1: CNV regions identified in 197 DNA samples. (Continued)Kalari et al. BMC Genomics 2010, 11:357
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study were observed in all three ethnic groups; 45 CNVs
were found in 2 ethnicities; and 32 CNVs were observed
in only one ethnic group (Table 1). No loci below 1% copy
number frequency were reported in this study.
We compared our loci to those in the structural varia-
tion table in the University of California Santa Cruz's
(UCSC) database http://genome.ucsc.edu. Figure 2 shows
an example on chromosome 22. Eighty-seven of the 102
loci that we identified overlapped with previously charac-
terized CNVs, and 51/102 had been identified in more
than one study. Of the 15 loci that had not been charac-
terized previously, no obvious differences in size or prev-
alence were observed, suggesting that these are likely to
be true CNVs and not the result of systematic error. In
Figure 2 we have superimposed our CNV values for a
portion of chromosome 22 over UCSC database data.
Divergence from the baseline indicates regions of CNV,
while amplitude represents prevalence. Figure 2 repre-
sents the overlap of our data (Illumina 550 + 650 K, Illu-
mina 550 K, Illumina 650 K) at the top with previous
reports at the bottom [7,11-13,21-25]. Lack of technical
bias between Illumina 550 K and 650 K data is also shown
since only the overlapping SNP set for the two platforms
was used (Figure 2).
We also had Affymetrix U133 Plus 2.0 expression array
data for the same 197 lymphoblastoid cell lines in which
we assayed CNV [18], which made it possible for us to
quantify the expression of genes linked to CNV s. Forty
one expression array probesets mapped close to (within
500 kb) or within the 102 CNV regions that we identified.
Of those 41 probesets, only 7 were expressed (17% (7/41)
when compared to the 28% of the 54,000 probesets across
the entire genome that were expressed) in the lympho-
blastoid cell lines, with an average expression value above
"100" using GCRMA normalization data (Additional file
1 Table S1).
chr19CNV97 20423788 20473895 50107 0.109 0.084 0.033 0.076
chr19CNV98 48066441 48387680 321239 0.127 0.084 0.133 0.111
chr20CNV99 14729882 14770129 40247 0.036 0.036 0.000 0.025
chr22CNV100 17270615 17376565 105950 0.036 0.000 0.033 0.020
chr22CNV101 20718332 21554058 835726 0.218 0.253 0.167 0.217
chr22CNV102 23994408 24239811 245403 0.055 0.060 0.033 0.051
Total 7805201
Average 76522
Median 19624
Minimum 90
The 102 CNV regions identified using the 197 DNA samples obtained from 3 ethnic groups.
Table 1: CNV regions identified in 197 DNA samples. (Continued)
Figure 1 Visualization of copy number regions identified in 15 
randomly selected samples using Bead studio software. Randomly 
selected individual samples are listed on the X-axis and chromosomes 
on the Y-axis. Each colored bar represents one CNV call. Colors indicate 
copy number; where dark red indicates copy # 0, dark orange indicates 
copy # 1, dark blue indicates copy # 3, blue violet indicates copy # 4+. 
The thickness of the band indicates the length of the CNV region.Kalari et al. BMC Genomics 2010, 11:357
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Gemcitabine and AraC IC50 value associations with CNVs
To identify gene(s) that might contribute to variation in
cytidine analog-induced cytotoxicity, we next analyzed
associations between CNVs and IC50 values for gemcit-
abine and AraC. We had previously performed gemcit-
abine and AraC cytotoxicity studies using the same cell
lines, as described previously [18]. IC50 values for both
drugs were used as phenotypes for the association stud-
ies, and the analysis was adjusted for race and gender. The
association studies with gemcitabine and AraC IC50 value
phenotypes resulted in the identification of 5 and 6 CNV
regions, respectively, that showed associations with p-val-
ues < 0.05 after 1000 permutations. Although these two
drugs are similar in structure, we did not observe any
common CNV regions that were significantly associated
with IC50 values for both gemcitabine and AraC. The
annotation and association results for gemcitabine and
A r a C  a r e  l i s t e d  i n  T a b l e s  2  a n d  3 ,  r e s p e c t i v e l y .
CNV validation using MLPA
T o experimentally validate CNVs that were significantly
associated with drug cytotoxicity, we tested the 11 CNVs
with permutated p-values for association that were less
than 0.05 using a high-throughput method designed to
quantify genomic content, multiplex ligation-dependent
probe amplification (MLPA). We were unable to amplify
one CNV (chr14CNV87:106047919-106066496). When
we compared MLPA to CNV values on a per-sample
basis, 173/197 samples matched our original QuantiSNP
CNV calls. Therefore, our original analysis had a zero
false positive rate for all but two regions (1.23%), and the
false negative rates ranged from 0% to 65% for the 10
regions that could be amplified (Additional file 1 Table
S2). The chr2CNV10 CNV, as shown in Table S2, had an
exceptionally high false negative rate, and we cannot rule
out the possibility that a SNP beneath the MLPA probe
might be responsible.
Functional characterization
To further characterize CNV regions, we identified genes
within 500 Kb of the 11 regions that were associated with
gemcitabine or AraC IC50 values. This relatively large
region was chosen because previous studies have shown
that cis-acting regulators can act over megabase distances
[26,27]. Two of the 5 regions that were significantly asso-
ciated with gemcitabine cytotoxicity contained a gene
within 500 Kb of the CNV. Both regions were on chromo-
some 11. One chromosome 11 region, 134154053-
134158019, had 25 SNPs associated with the CNV. The
nearest gene, B3GAT1, was 372016 bp distant from the
CNV (Table 2). The second chromosome 11 region,
5858528-5889688, had 12 SNPs associated with the CNV
and the OR52E4 gene overlapped this region.
In the case of AraC, one region (divided into 3 sub-
regions, as shown in Table 3) associated with AraC cyto-
toxicity was located on chromosome 22, with the nearest
gene  LRP5L  (low density lipoprotein receptor-related
protein 5-like), more than 3486 bases distant. Genes asso-
ciated with chromosome 2 and 12 regions were NPHP1
[nephronophthisis 1 (juvenile)], PLEKHA5  (pleckstrin
homology domain containing, family A member 5) and
GPR133 (G protein-coupled receptor 133), respectively.
NPHP1  and  PLEKHA5  overlapped the CNV regions,
whereas GPR133 was 179 Kb away from the CNV region
associated with AraC. The region located on chromo-
some 1 overlapped the KIF26B gene and was 295 Kb away
from a gene encoding a histone methyltransferase,
SMYD3.
Figure 2 Comparison of chromosome 22 CNV regions identified 
using our 197 cell line samples compared with the results of pre-
vious studies in the UCSC genome browser. The Illumina 550 + 650 
K (all samples combined), Illumina 550 K (CA, CEPH, HCA populations) 
and Illumina 650 K (AA samples) results in the diagram are from the 
present study, where spikes in the data indicate changes in CNV values. 
The "RefSeq Genes" row shows the locations of known genes in the hu-
man genome. In the "Structural Variation" tracks, green color indicates 
duplications, red indicates deletions, blue indicates both deletion and 
duplication, black represents an inversion and gray could be a gain or 
loss. "Conrad Dels" in the diagram are deletions detected by the analy-
sis of SNP genotypes using the HapMap Phase I data, release 16c.1, CEU 
and YRI samples [11]. "Hinds Dels" are deletions observed during hap-
loid hybridization analysis in 24 unrelated individuals from the Poly-
morphism Discovery Resource, selected for a SNP LD study [12]. "Iafrate 
CNVs" are from BAC microarray analysis of a population of 55 individu-
als [21]. "Locke CNVs" are CNV regions identified using array CGH in 269 
HapMap individuals [22]. "McCarroll Dels" are deletions from genotype 
analysis, performed with HapMap Phase I data, release 16a [13]. "Redon 
CNVs" are from SNP and BAC microarray analysis of HapMap Phase II 
data [7]. "Sebat CNVs" represents oligonucleotide microarray analysis 
performed with a population of 20 normal individuals [7]. "Sharp CNVs" 
represents putative CNV regions detected by BAC microarray analysis 
in a population of 47 individuals [24]. The "Tuzun Fosmids" row consists 
of fosmid mapping sites detected by mapping paired-end sequences 
from a human fosmid DNA library [25].Kalari et al. BMC Genomics 2010, 11:357
http://www.biomedcentral.com/1471-2164/11/357
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Since we had Affymetrix U133 Plus 2.0 mRNA expres-
sion array data for the same lymphoblastoid cell lines in
which we had assayed CNV [18]; we determined average
expression levels for all genes associated with the CNVs.
Although there were no probesets associated with
ORE52E4, we found that the average mRNA expression
levels after GCRMA normalization for probesets linked
with  B3GAT1, TYRP1, FAM5C, ADAM6, LRP5L,
PLEKHA5, KIF26B, NPHP1, FLJ40330, and GPR133 were
less than 10, suggesting either low or no expression of
these genes in lymphoblastoid cells. Therefore, no further
analysis was conducted with these candidates. However,
one of the genes associated with AraC IC50 had an aver-
age expression of 247 (SMYD3) in our cell lines and the
Table 2: Significant associations between gemcitabine IC50 values and CNV regions.
CNV ID Permutation 
P-value
Chromosome: 
Region
Number of 
SNPs
Length(bp) SNP start-SNP 
end
Nearest 
Gene(s)
chr9CNV58 0.027 chr9:12005741
-12098916
23 93176 rs10809674-
rs12351590
TYRP1
chr1CNV5 0.031 chr1:18779506
6-187809352
4 14287 rs382645-
rs269747
FAM5C
chr14CNV87 0.036 chr14:1060479
19-106066496
2 18578 rs4562969-
rs10151262
ADAM6
chr11CNV74 0.042 chr11:1341540
53-134211153
25 57101 rs1289444-
rs2155304
B3GAT1
chr11CNV65 0.043 chr11:5858528
-5889688
12 31161 rs1377518-
rs1453428
OR52E4
Association of CNV regions with the gemcitabine phenotype.
Table 3: Significant associations between AraC IC50 values and CNV regions.
CNV ID Permutation P-value Chromosome: Region Number 
of SNPs
Length (bp) SNP start-SNP end Nearest Gene(s)
chr22CNV102 0.013 chr22:24092010-24128856 5 36847 rs713878-rs84486 LRP5L
0.028 chr22:23999581-24091936 14 92356 rs6004527-rs713847 LRP5L
0.028 chr22:24135224-24239811 30 104588 rs13057190-rs2780695 LRP5L
chr2CNV10 0.016 chr2:89714801-89874746 9 159946 rs2847840-rs842164 FLJ40330
chr12CNV76 0.020 chr12:19364102-19442103 16 78002 rs12825616-rs2565666 PLEKHA5
chr1CNV7 0.035 chr1:243707190-243713984 6 6795 rs10737772-rs12121903 SMYD3,KIF26B
chr2CNV11 0.044 chr2:110243431-110315618 11 72188 rs3789735-rs17463266 NPHP1
chr12CNV83 0.047 chr12:130368913-130378451 5 9539 rs12319995-rs4759915 GPR133
Association of CNV regions with the AraC phenotype.Kalari et al. BMC Genomics 2010, 11:357
http://www.biomedcentral.com/1471-2164/11/357
Page 11 of 14
expression of this gene was also associated with AraC
IC50, with a p-value of 0.0027. The Chr1CNV7 associa-
tion did not pass Bonferroni correction. However, the
association study was a "discovery" study - to be followed
by functional genomics validation. Hence, we selected the
SMYD3 candidate gene based on expression and possible
biological relevance to cancer.
SMYD3 functional validation
It is known that knockdown of SMYD3 inhibits cervical
carcinoma cell growth and invasion [28] and that muta-
tions in the 5'-flanking region of SMYD3 may represent a
risk factor for human cancer [29]. It is also known that
SMYD3 plays crucial roles in HeLa cell proliferation and
migration/invasion, so it has been suggested that it may
be a useful therapeutic target in human cervical carcino-
mas [30]. As shown in Table 3, a CNV region located on
chromosome 1 close to the SMYD3 gene (chr1CNV7) is
associated with AraC IC50 value, with a permutation p-
value of 0.035. The chr1CNV7 deletion occurred in 3
samples, all from Caucasian subjects, so we also tested
the association in only this ethnic group. Likelihood ratio
testing of linear regression of AraC log IC50 values against
gender and storage time, with or without the relevant
CNV values, gave a p-value of 0.019. In addition, analysis
of IC50 values with the chr1CNV7 region showed that
deletion of this CNV region was associated with an
increase in the IC50 value for AraC (Table 4). To confirm
results obtained from the association study, we also per-
formed specific siRNA knockdown of the SMYD3 gene in
human MIApaca-2 pancreatic cancer cells, followed by
cytotoxicity studies. Down regulation of SMYD3 mRNA
by siRNA desensitized the pancreatic cancer cells to
AraC (P-value= 0.0011) when compared with cells trans-
fected with negative control siRNA (Figure 3), a direc-
tional change consistent with the results of our CNV
association study. Although, SMYD3 did not show a sig-
nificant association with gemcitabine cytotoxicity during
the association study, we also performed functional stud-
ies with that drug. We found that knockdown of the
SMYD3 gene also made MIApaca-2 cells more resistant
to gemcitabine (P-value = 0.0002) as shown in Figure 3.
The Chr1CNV7 copy number was associated with gem-
citabine IC50 values, (r-value = -0.01 and p-value =
0.804). While the p-value of association was insignificant,
the directionality of the association was consistent with
the results of the knockdown studies. In summary,
knockdown of SMYD3, followed by cytotoxicity studies
with both drugs, showed significant deviations, but the
deviation was small for AraC when compared to that
after gemcitabine treatment (Figure 3).
Finally, since the CNV close to the SMYD3 gene was
significantly associated with IC50, and since the func-
tional validation studies of SMYD3 agreed with the asso-
ciation study results, we expected that variation of mRNA
expression for SMYD3 in the cell lines might be signifi-
cantly correlated with IC50. SMYD3 mRNA expression
was significantly associated with IC50 value, with a p-
value of 0.028.
Discussion
CNV can occur as a result of genomic rearrangements
like deletion, duplication, inversion, and translocation.
Features such as the presence of repetitive elements, size
of the sequences, GC content, similarity and distance
between the sequences play a critical role in determining
susceptibility of regions to these rearrangement events
[31]. Many methods have been used successfully to iden-
tify CNV regions across the genome. The high density of
data from SNP platforms such as those of supplied by
Illumina or Affymetrix has not only allowed us to per-
form genome-wide association studies to identify geno-
types that are associated with a phenotype, but have also
made it possible to quantify SNP alleles (log R ratios and
B allele frequencies) for CNV. These log R ratios and B
allele frequencies can be used to discover CNV by apply-
ing computational algorithms. However, despite advances
in computational methods, the identification of interme-
diate sized CNVs (50 bp to 50 Kb) remains a challenge;
since detection of CNVs is based on the density and spac-
ing of probes on the platform.
In this study, we have used 550,000 SNP markers (Illu-
mina 550 K Bead chip) to discover CNV in 197 human
lymphoblastoid cell lines obtained from ethnically diverse
Table 4: AraC IC50 value mean, median and standard deviations for copy number values = 1 (deletion) and copy number 
value = 2 (normal).
AraC IC50 values (μmol)
CNV Value Mean Median Std Dev
1 1.177 1.092 0.486
2 -0.017 -0.180 0.998
Summary of IC50 values for copy number = 1 and copy number = 2.Kalari et al. BMC Genomics 2010, 11:357
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populations. The average distance between markers on
the Illumina 550 K chip is 5.8 kb, and the average size of
CNV s identified in our cell lines was more than 76,000
bp, indicating that smaller CNV may be underrepre-
sented in our study. The Illumina 550 K SNP chip was
designed, in part, to interrogate gene rich regions [32];
which is an advantage with regard to a lower probability
of our missing a gene-related CNV. We identified 775
CNVs in 102 regions with minor allele frequencies > 1%
(Table 1). Variables such as array, coverage, intensity and
CNV calling algorithms may all give different CNV calls.
Therefore, we used previous copy number findings repre-
sented in the structural variation table in the UCSC data-
base http://genome.ucsc.edu to compare with our CNVs
and found that the vast majority of variant loci (87 of 102)
were found in other publications, and 51/102 were repre-
sented in multiple studies. Although we did find agree-
ment for many of our CNVs with previously reported
variants, there were other CNV regions previously
reported that were not identified in our study. This could
be due to our stringent criteria for CNVs. It also could be
due to the different platforms, methods and study popu-
lations used in different studies. In addition rare events
are usually not reported.
It is known that variation in response to chemotherapy
results from many factors, including gender, race, envi-
ronmental factors and DNA sequence variation. DNA
sequence variation may include both SNPs and CNV.
Therefore, the presence of CNV is an important factor
that may contribute to variation in response to chemo-
therapy. Specifically, the existence of CNV within or near
a gene might result in differences in mRNA and protein
expression. To identify possible pharmacogenomic candi-
date genes that might be affected by CNV, we tested the
association of CNV with a drug response phenotype
(IC50) for gemcitabine and AraC using a 197 lymphoblas-
Figure 3 Functional characterization for the SMYD3 candidate gene with specific siRNA knockdown. (A) Knockdown of the SMYD3 gene in 
human MIApaca-2 pancreatic cancer cells resulted in increased resistance to both AraC and gemcitabine as determined by MTS assay. SEM values for 
3 independent experiments were so small that they are contained within the symbols. (B) Quantitative RT-PCR for SMYD3 in MIApaca-2 cells. Error bars 
represent SEM values for three independent experiments.Kalari et al. BMC Genomics 2010, 11:357
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toid cell line-based model system designed to make it
possible to study common human genetic variation.
Although tumor genome is critical for understanding
response to therapy and disease pathophysiology, the ger-
mline genome is also critical, especially for drug response
phenotypes. Obviously, we understand that these lym-
phoblastoid cell lines were EBV transformed from normal
individuals, and that they were neither collected from
cancer patients nor tumor tissues. Hence, we might miss
some candidate genes that may be specific to cancer.
However, lymphoblastoid cell lines have been shown by
several groups, including ours, to be useful for identifying
candidate genes or genetic variation associated with
drug-induced cytotoxicity [18,33-37]. Therefore, in this
study we also used these lymphoblastoid cell lines to
study the possible contribution of CNVs to variation in
drug response. To begin the process of understanding
how variation in copy number might affect drug response
phenotypes for gemcitabine and AraC, we correlated 775
CNVs with IC50 values in 197 lymphoblastoid cell lines.
11/102 regions were associated with gemcitabine and
AraC IC50 values (Tables 2 and 3). We then performed
MLPA to compare with and to validate the in-silico
QuantiSNP CNV calls.
Since we had Affymetrix U133 Plus 2.0 expression array
data for the same lymphoblastoid cell lines [18]; we deter-
mined expression levels for genes surrounding the 11
CNV regions. The B3GAT1, LRP5L, PLEKHA5, KIF26B,
NPHP1, TYRP1, FAM5C, ADAM6, FLJ40330, and
GPR133  genes had low expression. Only one CNV on
chromosome 1 (chr1CNV7) had a gene (SMYD3) in close
proximity that displayed high expression in the lympho-
blastoid cell lines.
SMYD3, found on the q arm of chromosome 1, encodes
an alternatively spliced transcript for 369 or 428 amino
acids protein. Hamamoto et. al. first described SMYD3's
histone methyltransferase activity with specificity for di-
and tri- methylation of lys4 on Histone 3. SMYD3's his-
tone methyltransferase activity results in transcription
induction for at least 60 targets across the genome [38].
Enhanced expression of SMYD3 has been observed in
numerous tumors including colorectal, hepatocellular
[38] and breast cancer [39]. Overexpression experiments
of SMYD3 have repeatedly shown to increase the rate of
cell proliferation [38-40], while knockdown experiments
result in decrease cell proliferation and cell migration
while increasing apoptosis [28,41]. Our studies indicated
the association of the chr1CNV7 with AraC cytotoxicity
as well as correlation with SMYD3 expression. Functional
validations of our results were performed with knock-
down of the SMYD3 gene in pancreatic cancer cell lines.
Knockdown made the cells more resistant to AraC, con-
firming the association study results, and also made them
resistant to gemcitabine. Our results suggest that joining
association studies with functional validation experi-
ments may help to identify biomarkers for disease or
response to therapy.
Conclusions
We took the advantage of genome-wide SNP data
obtained with 550 K Illumina Bead Chips to identify
CNV regions across the genome in 197 lymphoblastoid
cell lines. Association studies with gemcitabine and AraC
cytotoxicity phenotypes identified CNV regions that
might be associated with cytotoxicity for these two drugs.
In this study we investigated the role of CNV s together
with expression of neighboring genes (B3GAT1, LRP5L,
PLEKHA5, KIF26B, TYRP1, FAM5C, ADAM6, FLJ40330,
NPHP1, OR52E4, GPR133 and  SMYD3) with drug
response phenotypes. Analysis in lymphoblastoid cell
lines and functional validation in cancer cell lines suggest
the probable role of SMYD3 to AraC and gemcitabine
drug response phenotype. The current study provides
additional information with regard to the contribution of
CNVs to variation in drug response for two important
antineoplastic drugs and indicates that the assay of CNV
should be included in pharmacogenomic studies.
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